These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Role of oncoproteomics in the personalized management of cancer. Jain KK Expert Rev Proteomics; 2004 Jun; 1(1):49-55. PubMed ID: 15966798 [TBL] [Abstract][Full Text] [Related]
6. Integrative oncoproteomics strategies for anticancer drug discovery. Liu R; Wang K; Yuan K; Wei Y; Huang C Expert Rev Proteomics; 2010 Jun; 7(3):411-29. PubMed ID: 20536311 [TBL] [Abstract][Full Text] [Related]
7. Clinical cancer proteomics: promises and pitfalls. Alaiya A; Al-Mohanna M; Linder S J Proteome Res; 2005; 4(4):1213-22. PubMed ID: 16083271 [TBL] [Abstract][Full Text] [Related]
8. Proteomics: new technologies and clinical applications. Latterich M; Abramovitz M; Leyland-Jones B Eur J Cancer; 2008 Dec; 44(18):2737-41. PubMed ID: 18977654 [TBL] [Abstract][Full Text] [Related]
9. Cancer biomarkers: current issues and future directions. Jain KK Curr Opin Mol Ther; 2007 Dec; 9(6):563-71. PubMed ID: 18041667 [TBL] [Abstract][Full Text] [Related]
10. Cancer proteomics and its application to discovery of therapy response markers in human cancer. Smith L; Lind MJ; Welham KJ; Cawkwell L; Cancer; 2006 Jul; 107(2):232-41. PubMed ID: 16752413 [TBL] [Abstract][Full Text] [Related]
11. Personalized medicine in oncology: tailoring the right drug to the right patient. Jiang Y; Wang M Biomark Med; 2010 Aug; 4(4):523-33. PubMed ID: 20701441 [TBL] [Abstract][Full Text] [Related]
12. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. Lee JW; Figeys D; Vasilescu J Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683 [TBL] [Abstract][Full Text] [Related]
13. Proteomics-driven cancer biomarker discovery: looking to the future. Simpson RJ; Bernhard OK; Greening DW; Moritz RL Curr Opin Chem Biol; 2008 Feb; 12(1):72-7. PubMed ID: 18295612 [TBL] [Abstract][Full Text] [Related]
15. Proteomic approaches in cancer risk and response assessment. Petricoin EF; Liotta LA Trends Mol Med; 2004 Feb; 10(2):59-64. PubMed ID: 15102358 [TBL] [Abstract][Full Text] [Related]
16. Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways. Sun S; Lee NP; Poon RT; Fan ST; He QY; Lau GK; Luk JM Liver Int; 2007 Oct; 27(8):1021-38. PubMed ID: 17845530 [TBL] [Abstract][Full Text] [Related]
17. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents. O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026 [TBL] [Abstract][Full Text] [Related]
18. Cancer: a proteomic disease. Li G; Xiao Z; Liu J; Li C; Li F; Chen Z Sci China Life Sci; 2011 May; 54(5):403-8. PubMed ID: 21455689 [TBL] [Abstract][Full Text] [Related]
19. Proteomic approaches for serum biomarker discovery in cancer. Maurya P; Meleady P; Dowling P; Clynes M Anticancer Res; 2007; 27(3A):1247-55. PubMed ID: 17593616 [TBL] [Abstract][Full Text] [Related]
20. Evolving 'omics' technologies for diagnostics of head and neck cancer. Nagaraj NS Brief Funct Genomic Proteomic; 2009 Jan; 8(1):49-59. PubMed ID: 19273537 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]